

***Fiscal Year 2024 Department of Defense Peer Reviewed Medical Research Program (PRMRP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Clinical Trial Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942524PRMRPCTA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> <li>• <b><i>Preproposal submission is required; application submission is by invitation only.</i></b></li> <li>• Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition in the Topic Area(s) of interest.</li> <li>• Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials.</li> <li>• Two options will be offered: <ul style="list-style-type: none"> <li>○ <b><u>Planning Phase with Clinical Trial Option:</u></b> Provides support to prepare and submit an Investigational New Drug/ Investigational Device Exemption (IND/ IDE) application to the U.S. Food and Drug Administration (FDA) and requires FDA/regulatory approval or exemption to proceed before the clinical trial may be funded.</li> <li>○ <b><u>Clinical Trial Only Option:</u></b> Provides support for the clinical trial. IND or IDE applications to the FDA, if needed, must be approved by the FDA and included in the application submission.</li> </ul> </li> </ul>	<p><b><u>Clinical Trial:</u></b></p> <ul style="list-style-type: none"> <li>• A funding limit is not defined; requested funding must be appropriate for the scope of work proposed.</li> <li>• The maximum period of performance for the clinical trial is <b>4</b> years.</li> </ul> <p><b><u>Planning Phase with Clinical Trial Option:</u></b></p> <ul style="list-style-type: none"> <li>• The maximum allowable funding for the Planning Phase period of performance is <b>\$500,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance for the planning phase is <b>12</b> months.</li> <li>• The maximum period of performance for the clinical trial is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Preproposal):</b> May 13, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> August 19, 2024 11:59 p.m. Eastern time</p>
<p><b>Discovery Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942524PRMRPDA</p>	<p>Postdoctoral fellow or clinical fellow (or equivalent) and above</p>	<ul style="list-style-type: none"> <li>• Supports innovative, untested, non-incremental, high-risk/potentially high-reward research that will provide new insights, paradigms, technologies or applications.</li> <li>• Not intended to support the logical progression of an already established line of questioning.</li> <li>• <b><i>Clinical trials will not be funded.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$275,000</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>2</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> May 6, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> May 23, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Investigator-Initiated Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942524PRMRPIIRA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports research that will make an important contribution toward research, patient care and/or quality of life for a disease of condition in the Topic Area(s) of interest.</li> <li>• <i>Clinical trials will not be funded.</i></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$1.0 million</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> May 6, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> May 23, 2024 11:59 p.m. Eastern time</p>
<p><b>Impact Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942524PRMRPIPA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports applied research, defined as use-inspired and practice-oriented science that brings together outcomes from basic research, and insights from real-world environment to foster clinical applicability in the Topic Area(s) of interest.</li> <li>• Partnering Principal Investigator Option available.</li> <li>• <i>Clinical trials will not be funded.</i></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$2.0 million</b> for direct costs for single investigators and <b>\$2.6 million</b> for partnering investigators.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> May 13, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> June 6, 2024 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Lifestyle and Behavioral Health Interventions Research Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942524PRMRPLBIRA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports using a combination of scientific disciplines including behavioral health, psychology, psychometrics, biostatistics and epidemiology, surveillance and public health that will enhance patient experience and improve outcomes.</li> <li>• Projects may include clinical research or clinical trials for <i>interventions that do not require regulation by the FDA</i>.</li> <li>• Encourages patient advocate participation in the research team.</li> <li>• <i>Animal studies will not be funded.</i></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$3.0 million</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> May 13, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> June 6, 2024 11:59 p.m. Eastern time</p>
<p><b>Technology/Therapeutic Development Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p>HT942524PRMRPTTDA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> <li>• Supports the translation of promising preclinical findings into products for clinical applications including prevention, detection, diagnosis, treatment, and/or quality of life.</li> <li>• Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product.</li> <li>• <i>Clinical trials will not be funded.</i></li> </ul>	<ul style="list-style-type: none"> <li>• The maximum allowable funding for the entire period of performance is <b>\$4.0 million</b> for direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.</li> <li>• The maximum period of performance is <b>4</b> years.</li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> May 13, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> June 6, 2024 11:59 p.m. Eastern time</p>